Search

Takeda Pharmaceutical Co Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

16.36 -0.91

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

16.23

Max

16.57

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-130B

-25B

Pardavimai

-99B

1.1T

P/E

Sektoriaus vid.

42.622

60.149

Pelnas, tenkantis vienai akcijai

0.21

Dividendų pajamingumas

3.72

Pelno marža

-2.222

Darbuotojai

47,029

EBITDA

-298B

158B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+28.13% upside

Dividendai

By Acuity

Dividendų pajamingumas

Sektoriaus vid.

3.72%

2.24%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

976M

53B

Ankstesnė atidarymo kaina

17.27

Ankstesnė uždarymo kaina

16.36

Naujienos nuotaikos

By Acuity

100%

0%

327 / 342 reitingas Healthcare

Takeda Pharmaceutical Co Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-14 23:46; UTC

News

PayPal Holdings Inc. shares are lower in after-market trading despite expanding buy now, pay later options in the UK with a new Pay in 30 Days feature.

2026-07-14 23:41; UTC

Event
News

Biogen Inc shares are higher in after-market trading following positive Phase 2 CELIA study results for diranersen, which targets tau in early Alzheimer's disease.

2026-07-14 23:32; UTC

Social Media
News

Advanced Micro Devices shares rose in after-market hours following price target increases by analysts, including KeyBanc's $725 target amid strong demand for EPYC processors.

2026-07-14 23:32; UTC

News
Social Media

Micron Technology's stock rose in after-market trading following a lower-than-expected inflation report and positive sentiment from IBM regarding memory chip demand.

2026-07-14 23:31; UTC

News
Social Media

Amazon.com Inc shares are higher in after-market trading amid positive sentiment. Analysts maintain a bullish outlook on the company's long-term investment strategy.

2026-07-14 23:31; UTC

News

Netflix shares are higher in after-hours trading, buoyed by investor confidence despite rising subscription costs and regulatory scrutiny amid broader positive market sentiment.

2026-07-14 23:31; UTC

News
Social Media

Alphabet Inc signed a fixed-price power purchase agreement for its largest solar-plus-storage project in the U.S. Shares are lower in after-market hours.

2026-07-14 23:31; UTC

News
Correlated Moves

Apple Inc. shares were little changed after KeyBanc downgraded the rating to Sell with a price target of $250. OpenAI countered Apple's trade secret lawsuit claims.

2026-07-14 23:11; UTC

News

The Australian Dollar is trading higher against the Singapore Dollar, supported by rising crude oil prices and improved U.S. inflation data.

2026-07-14 23:06; UTC

News

Fiserv Inc. will release its second-quarter earnings on August 6, 2026, with shares trading higher in after-market hours amid positive sentiment.

2026-07-14 23:06; UTC

News

Workday Inc. shares declined slightly in after-market trading following a challenging year, despite reporting 14.7% year-over-year growth in subscription revenue.

2026-07-14 23:06; UTC

Macro News
News
Correlated Moves
ETF Constituents

Health Care Select Sector SPDR Fund is trading higher after proposed Medicare reforms by CMS and Anthem's new Alzheimer's testing coverage announcement.

2026-07-14 23:06; UTC

News

United States Oil Fund LP trades higher in after-market hours as Iran withdraws from its agreement with the U.S., raising oil supply stability concerns.

2026-07-14 23:01; UTC

News

Cintas Corp is higher in after-market trading, with its market capitalization surpassing Target Corp, positioning it 193rd in the S&P 500.

2026-07-14 22:32; UTC

Correlated Moves
News

Geopolitical tensions and rising crude oil prices have contributed to an increase in CHF/HKD since Monday's close, reflecting broader market sentiment.

2026-07-14 20:52; UTC

Correlated Moves
News

Vanguard Total Bond Market ETF advances in after-hours trading following a significant drop in the U.S. Consumer Price Index, easing inflation concerns and boosting Treasury demand.

2026-07-14 20:07; UTC

News
Social Media

eBay shares are lower amid mixed analyst ratings and social media concerns about growth metrics. Jefferies raised the price target to $75 while maintaining an Underperform rating.

2026-07-14 20:07; UTC

News

Xcel Energy shares are lower amid a settlement proposal for a $123 million revenue increase, with regulatory hearings scheduled for July 2026.

2026-07-14 20:07; UTC

Social Media
Correlated Moves
News
Macro Event

Gold prices rose sharply today, with August futures reaching $4,092 an ounce after cooler CPI data. SPDR Gold Shares also benefited from this upward trend.

2026-07-14 20:07; UTC

News
Social Media

Electronic Arts is set to launch EA Sports Madden NFL 27 Arcade Edition on August 6, contributing to positive investor sentiment as shares trade higher.

2026-07-14 20:02; UTC

News
Macro Event

American Airlines shares are lower amid mixed options sentiment and elevated trading volume. The stock is set to report earnings on July 23.

2026-07-14 20:02; UTC

Correlated Moves
News

Intuitive Surgical shares are lower as Baird cuts price target to $525 from $610. The stock has reached a 25-month low at $395.02.

2026-07-14 20:02; UTC

News
Macro Event

Take-Two Interactive shares are trading lower amid recent inflation data, despite earlier gains during the session reflecting broader market pressures in the gaming sector.

2026-07-14 19:56; UTC

News

Citigroup maintained its Buy rating on Monster Beverage and raised the price target to $113, contributing to a higher stock price since Monday's close.

2026-07-14 19:52; UTC

Correlated Moves
ETF Constituents
News

Fitch affirmed Canada's credit rating at AA+, boosting sentiment for Canadian assets. The iShares MSCI Canada ETF is trading higher, supported by favorable USD/CAD movement.

2026-07-14 19:52; UTC

Macro Event
News

NTAL launched to amplify daily participation in NTAP amid strong activity.

2026-07-14 19:46; UTC

News

Marriott International shares rise amid positive sentiment from a new collaboration between The Ritz-Carlton and MERIT Beauty, with Macquarie raising its price target to $365.

2026-07-14 19:45; UTC

News
Correlated Moves

Intuit Inc. shares are lower amid a class action lawsuit alleging securities fraud and an investigation into potential violations of federal securities laws.

2026-07-14 19:41; UTC

Correlated Moves
Macro Event
News

U.S. CPI showed a month-over-month decrease, boosting demand for Treasury bonds. The iShares 20+ Year Treasury Bond ETF remains higher than Monday's close.

2026-07-14 19:37; UTC

News
Social Media

KeyBanc maintains Overweight rating on Intel, raising price target to $155. Strong demand for AI-driven CPUs and improved yields support upward movement in shares today.

Akcijų palyginimas

Kainos pokytis

Takeda Pharmaceutical Co Ltd ADR Prognozė

Kainos tikslas

By TipRanks

28.13% į viršų

12 mėnesių prognozė

Vidutinis 21 USD  28.13%

Aukščiausias 21 USD

Žemiausias 21 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Takeda Pharmaceutical Co Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
help-icon Live chat